Developer docs
API playgroundTry for free, no card

Search company profiles

Slayback Pharma

Full company profile

uuid0002hwk

Namestring
Slayback Pharma
Legal namestring
Azurity Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Slayback Pharma is a specialty pharmaceutical company founded in 2011, headquartered in Princeton, United States, with 101-250 employees. The company develops and commercializes a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 therapeutic areas, including cardiovascular, central nervous system, oncology, endocrinology, gastrointestinal, hematology, immunology, allergy, anti-infective, and respiratory. Slayback's stated focus is on serving "overlooked patients" — populations underserved by traditional pharmaceutical approaches — through practical, administration-friendly formulations.

The company operates a Next-Gen Commercial Model leveraging data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Its distribution architecture is multi-channel and global, spanning 50+ countries and incorporating pharmacy distribution, patient-direct programs, and clinical kits for institutional settings. Recent strategic activity includes the FDA approval of an Aprepitant Injectable Emulsion for supportive oncology care (June 2026), new product launches such as Ferabright, Javadin, and Xifyrm, and a partnership with ACA Pharma to expand ferumoxytol-based products into Macau and Greater China.

Slayback has raised approximately $110M in disclosed growth funding from marquee private equity sponsors Kohlberg Kravis Roberts & Co. ($60M, 2017) and Everstone ($50M, 2020). The company remains privately held. Its revenue model is anchored in one-time product sales across its pharmaceutical portfolio, with pricing conducted on a quote basis through pharmacy and institutional channels rather than publicly disclosed list pricing.

Short descriptiontext

Slayback Pharma is a privately held specialty pharmaceutical company with 50+ medicines across 10 therapeutic areas and a 50+ country footprint, focused on serving overlooked patient populations through practical, administration-friendly formulations and multi-channel global distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, generic drug development, prescription medicines, complex generic formulations, pharmaceutical drug delivery
Industry2 codes
PRIMARYHLAIABAB
Complex Generics (e.g., inhalation, transdermal, liposomal)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Azurity generates revenue through the sale of specialty pharmaceutical products across 10 therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a portfolio of 50+ medicines spanning 10 dosage forms.

azurity.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Slayback Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and branded prescription medicines across multiple therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a diversified portfolio of 50+ medicines spanning 10 dosage forms, with a focus on overlooked patient populations requiring specialized formulations and administration-friendly treatment options.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Millions of people have benefited from Azurity medicines globally
Product and service7 records
1FerabrightTM
CategoryHematology Pharmaceuticals
Description

Ferumoxytol-based pharmaceutical product for iron deficiency treatment, distributed globally through regulatory and distribution partners.

2JavadinTM
CategoryCardiovascular Pharmaceuticals
Description

Cardiovascular pharmaceutical product for patients with cardiac conditions.

3Feraheme
CategoryHematology Pharmaceuticals
Description

Ferumoxytol-based intravenous iron replacement product for treatment of iron deficiency anemia.

4Cardiovascular/Cardiology Portfolio
CategoryCardiovascular Pharmaceuticals
Description

Portfolio of cardiovascular medicines including BiDil, EDARBI, EDARBYCLOR, EPANED, KATERZIA, LANOXIN, QBRELIS, SOTYLIZE, SULAR, WIDAPLIK, and JAVADIN for treatment of cardiovascular conditions.

5CNS/Cerebrovascular Portfolio
CategoryCNS Pharmaceuticals
Description

Central nervous system medicines including ARYNTA, EPRONTIA, EVEKEO, FERABRIGHT, FLEQSUVY, HORIZANT, NYMALIZE, XIFYRM, ZENZEDI, ZONISADE for CNS and cerebrovascular disorders.

6Gastrointestinal Portfolio
CategoryGastrointestinal Pharmaceuticals
Description

Gastrointestinal medicines including KONVOMEP, PRILOSEC, SUFLAVE, SUPREP, SUTAB for GI conditions and bowel preparation.

7Oncology Portfolio
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-21
Description

ACA Pharma and Azurity Pharmaceuticals announced regulatory approval of Feraheme and Ferabright in Macau, marking expansion of ferumoxytol-based products across key Asian markets. This partnership advances regulatory pathways and improves patient access throughout Greater China.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Azurity is the parent/acquirer entity under which the Slayback-branded portfolio has been integrated. Operates the same specialty-pharma business model with overlapping therapeutic-area focus (cardiovascular, CNS, oncology, endocrinology) and shares the 50+ country commercial footprint, making it the closest direct comparability anchor.

TypeDirect peer
Description

ANI is a U.S.-based specialty and generic pharmaceutical company with a similar strategy of acquiring and commercializing differentiated, often off-patent or under-promoted prescription products across multiple therapeutic areas — directly comparable to Slayback/Azurity's "overlooked patient" positioning.

TypeDirect peer
Description

Amneal combines specialty, branded, and generics in a diversified portfolio across neurology, endocrinology, and other therapeutic areas. Its branded Specialty segment competes head-to-head with Azurity/Slayback on reformulations and administration-friendly formats for underserved patient populations.

TypeDirect peer
Description

Mallinckrodt is a specialty pharma focused on brands in CNS, autoimmune, and rare/orphan conditions — overlapping with Slayback/Azurity's CNS, immunology, and oncology-support products and following a similar strategy of revitalizing niche or deprioritized assets.

TypeDirect peer
Description

Upsher-Smith is a privately held U.S. specialty/generic pharma with a portfolio spanning CNS, cardiology, and dermatology. Comparable mid-sized, sponsor-backed company (historically PE-owned) with a similar niche-brand revitalization playbook.

6Padagis
TypeDirect peer
Description

Padagis (formerly Perrigo's generics business) is a specialty generics and OTC company with an extensive branded specialty portfolio. Comparable business model of operating niche, often-deprioritized prescription brands across multiple therapeutic categories.

7Endo International
TypeDirect peer
Description

Endo operates a specialty pharma business (branded sterile injectables, urology, endocrinology) that overlaps with Slayback/Azurity's endocrinology and supportive-care product set, with a similar focus on differentiated formulations and lifecycle management.

TypeEmerging player
Description

Cumberland is a smaller U.S. specialty pharma focused on hospital and gastroenterology products. Comparable in targeting underserved therapeutic niches with differentiated branded formulations, though materially smaller in scale and geographic reach than Slayback/Azurity.

TypeEmerging player
Description

Sentynl is a PE-backed (Zydus Group) specialty pharma focused on commercializing niche and rare-disease products — directly comparable "overlooked patient" niche strategy and sponsor profile to Slayback/Azurity.

TypeBroad incumbent
Description

Bausch Health's specialty pharma (Salix, Bausch + Lomb Rx) competes in GI, CNS, and ophthalmology categories where Slayback/Azurity has assets (SUPREP, SUTAB, HORIZANT, XATMEP). Larger and broader portfolio, but overlapping therapeutic focus makes it a useful incumbent benchmark.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Slayback Pharma

Specialty Pharmaceuticalsslayback-pharma.com

Slayback Pharma is a privately held specialty pharmaceutical company with 50+ medicines across 10 therapeutic areas and a 50+ country footprint, focused on serving overlooked patient populations through practical, administration-friendly formulations and multi-channel global distribution.

What Slayback Pharma does

Slayback Pharma is a specialty pharmaceutical company founded in 2011, headquartered in Princeton, United States, with 101-250 employees. The company develops and commercializes a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 therapeutic areas, including cardiovascular, central nervous system, oncology, endocrinology, gastrointestinal, hematology, immunology, allergy, anti-infective, and respiratory. Slayback's stated focus is on serving "overlooked patients" — populations underserved by traditional pharmaceutical approaches — through practical, administration-friendly formulations.

The company operates a Next-Gen Commercial Model leveraging data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Its distribution architecture is multi-channel and global, spanning 50+ countries and incorporating pharmacy distribution, patient-direct programs, and clinical kits for institutional settings. Recent strategic activity includes the FDA approval of an Aprepitant Injectable Emulsion for supportive oncology care (June 2026), new product launches such as Ferabright, Javadin, and Xifyrm, and a partnership with ACA Pharma to expand ferumoxytol-based products into Macau and Greater China.

Slayback has raised approximately $110M in disclosed growth funding from marquee private equity sponsors Kohlberg Kravis Roberts & Co. ($60M, 2017) and Everstone ($50M, 2020). The company remains privately held. Its revenue model is anchored in one-time product sales across its pharmaceutical portfolio, with pricing conducted on a quote basis through pharmacy and institutional channels rather than publicly disclosed list pricing.

Slayback Pharma firmographics

Firmographics
Name
Slayback Pharma
Legal name
Azurity Pharmaceuticals, Inc.
Website
https://slayback-pharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Slayback Pharma is a privately held specialty pharmaceutical company with 50+ medicines across 10 therapeutic areas and a 50+ country footprint, focused on serving overlooked patient populations through practical, administration-friendly formulations and multi-channel global distribution.
Ownership category
akta.pro rank

Slayback Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAB
Complex Generics (e.g., inhalation, transdermal, liposomal)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Specialty pharmaceuticals
  • Generic drug development
  • Prescription medicines
  • Complex generic formulations
  • Pharmaceutical drug delivery

Where Slayback Pharma is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Slayback Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Azurity generates revenue through the sale of specialty pharmaceutical products across 10 therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a portfolio of 50+ medicines spanning 10 dosage forms.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Slayback Pharma product offering

Product offering

Core offering

Slayback Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and branded prescription medicines across multiple therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a diversified portfolio of 50+ medicines spanning 10 dosage forms, with a focus on overlooked patient populations requiring specialized formulations and administration-friendly treatment options.

Differentiator

Problem solved

Functional benefit

Products and services

  • FerabrightTM Ferumoxytol-based pharmaceutical product for iron deficiency treatment, distributed globally through regulatory and distribution partners.
  • JavadinTM Cardiovascular pharmaceutical product for patients with cardiac conditions.
  • Feraheme Ferumoxytol-based intravenous iron replacement product for treatment of iron deficiency anemia.
  • Cardiovascular/Cardiology Portfolio Portfolio of cardiovascular medicines including BiDil, EDARBI, EDARBYCLOR, EPANED, KATERZIA, LANOXIN, QBRELIS, SOTYLIZE, SULAR, WIDAPLIK, and JAVADIN for treatment of cardiovascular conditions.
  • CNS/Cerebrovascular Portfolio Central nervous system medicines including ARYNTA, EPRONTIA, EVEKEO, FERABRIGHT, FLEQSUVY, HORIZANT, NYMALIZE, XIFYRM, ZENZEDI, ZONISADE for CNS and cerebrovascular disorders.
  • Gastrointestinal Portfolio Gastrointestinal medicines including KONVOMEP, PRILOSEC, SUFLAVE, SUPREP, SUTAB for GI conditions and bowel preparation.
  • Oncology Portfolio

Quantifiable outcome

  • Millions of people have benefited from Azurity medicines globally

Companies that use Slayback Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Slayback Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Slayback Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ACA PharmacoreChannel Partner/ Reseller/ Distributor · 21 May 2026ACA Pharma and Azurity Pharmaceuticals announced regulatory approval of Feraheme and Ferabright in Macau, marking expansion of ferumoxytol-based products across key Asian markets. This partnership advances regulatory pathways and improves patient access throughout Greater China.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Slayback Pharma competitors and assessment

Company assessment

Direct peers

  • Azurity Pharmaceuticals: Azurity is the parent/acquirer entity under which the Slayback-branded portfolio has been integrated. Operates the same specialty-pharma business model with overlapping therapeutic-area focus (cardiovascular, CNS, oncology, endocrinology) and shares the 50+ country commercial footprint, making it the closest direct comparability anchor.
  • ANI Pharmaceuticals: ANI is a U.S.-based specialty and generic pharmaceutical company with a similar strategy of acquiring and commercializing differentiated, often off-patent or under-promoted prescription products across multiple therapeutic areas — directly comparable to Slayback/Azurity's "overlooked patient" positioning.
  • Amneal Pharmaceuticals: Amneal combines specialty, branded, and generics in a diversified portfolio across neurology, endocrinology, and other therapeutic areas. Its branded Specialty segment competes head-to-head with Azurity/Slayback on reformulations and administration-friendly formats for underserved patient populations.
  • Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharma focused on brands in CNS, autoimmune, and rare/orphan conditions — overlapping with Slayback/Azurity's CNS, immunology, and oncology-support products and following a similar strategy of revitalizing niche or deprioritized assets.
  • Upsher-Smith Laboratories: Upsher-Smith is a privately held U.S. specialty/generic pharma with a portfolio spanning CNS, cardiology, and dermatology. Comparable mid-sized, sponsor-backed company (historically PE-owned) with a similar niche-brand revitalization playbook.
  • Padagis: Padagis (formerly Perrigo's generics business) is a specialty generics and OTC company with an extensive branded specialty portfolio. Comparable business model of operating niche, often-deprioritized prescription brands across multiple therapeutic categories.
  • Endo International: Endo operates a specialty pharma business (branded sterile injectables, urology, endocrinology) that overlaps with Slayback/Azurity's endocrinology and supportive-care product set, with a similar focus on differentiated formulations and lifecycle management.

Emerging players

  • Cumberland Pharmaceuticals: Cumberland is a smaller U.S. specialty pharma focused on hospital and gastroenterology products. Comparable in targeting underserved therapeutic niches with differentiated branded formulations, though materially smaller in scale and geographic reach than Slayback/Azurity.
  • Sentynl Therapeutics: Sentynl is a PE-backed (Zydus Group) specialty pharma focused on commercializing niche and rare-disease products — directly comparable "overlooked patient" niche strategy and sponsor profile to Slayback/Azurity.

Broad incumbents

  • Bausch Health: Bausch Health's specialty pharma (Salix, Bausch + Lomb Rx) competes in GI, CNS, and ophthalmology categories where Slayback/Azurity has assets (SUPREP, SUTAB, HORIZANT, XATMEP). Larger and broader portfolio, but overlapping therapeutic focus makes it a useful incumbent benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Slayback Pharma social profiles

Digital presence

Slayback Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Slayback Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Slayback Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Slayback Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Slayback Pharma

What does Slayback Pharma do?

Slayback Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and branded prescription medicines across multiple therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a diversified portfolio of 50+ medicines spanning 10 dosage forms, with a focus on overlooked patient populations requiring specialized formulations and administration-friendly treatment options.

Is Slayback Pharma a public or private company?

Slayback Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Slayback Pharma founded?

Slayback Pharma was founded in 2019. It employs 11 to 50 people.

Where is Slayback Pharma based?

Slayback Pharma is headquartered in Princeton, United States, in the North America region.

How does Slayback Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Slayback Pharma's main competitors?

Direct peers on record are Azurity Pharmaceuticals, ANI Pharmaceuticals, Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Padagis and Endo International. Emerging players are Cumberland Pharmaceuticals and Sentynl Therapeutics. Bausch Health is listed as a broad incumbent.

Does Slayback Pharma have an API?

No public API is recorded for Slayback Pharma.

What industry is Slayback Pharma in?

Slayback Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAB, Complex Generics (e.g., inhalation, transdermal, liposomal), with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Azurity PharmaceuticalsAzurity Pharmaceuticals Acquires Slayback PharmaAzurity Pharmaceuticals, Inc. has acquired Slayback Pharma LLC, closing the transaction on September 27, 2023. The acquisition is expected to enhance Azurity's ability to launch new medicines and expand its product portfolio by combining the strengths of both companies. The merger aims to improve access to healthcare for overlooked patients through innovative pharmaceuticals.BenzingaAzurity Pharmaceuticals Acquires Slayback PharmaAzurity Pharmaceuticals has completed its acquisition of Slayback Pharma, making Slayback a wholly-owned subsidiary of Azurity. The acquisition is expected to enhance Azurity's capabilities and lead to the launch of numerous new medicines targeting overlooked patients. The combined strengths of the two companies aim to improve the development of innovative therapies to meet diverse medical needs.private-equitynews.comAzurity Pharmaceuticals acquires KKR-backed Slayback PharmaAzurity Pharmaceuticals has completed the acquisition of Slayback Pharma from investors KKR and Everstone Capital, making Slayback a wholly-owned subsidiary. This strategic combination merges Azurity's commercial expertise with Slayback's R&D capabilities to expand their pipeline of innovative dose-form medicines for overlooked patients.MarketScreenerKKR : Azurity Pharmaceuticals Acquires KKR-backed Slayback PharmaAzurity Pharmaceuticals has completed the acquisition of Slayback Pharma from existing investors including KKR and Everstone Capital, making Slayback a wholly-owned subsidiary. This combination merges Azurity's commercial capabilities with Slayback's R&D platform to expand their combined pipeline of innovative dose-form medicines for overlooked patients. The deal is expected to accelerate Azurity's strategic growth plan by enabling more frequent launches of new drug products.BioSpaceEndo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection)Endo announced an agreement with Slayback Pharma to distribute Prevduo, a neostigmine-glycopyrrolate injection, exclusively in the U.S. The FDA approved the product in February 2023 for reversing neuromuscular blocking agents after surgery. Endo expects to launch the product in June 2023.BusinessLineDr Reddy’s inks licensing pact with Slayback Pharma for Lumify in USDr Reddy's licensed Slayback Pharma's Brimonidine Tartrate Ophthalmic Solution, the private label equivalent of Lumify, for the US market. Slayback filed the first ANDA under Paragraph IV, and Dr Reddy's gets exclusive rights outside the US. The US total addressable market is about $130 million for the 52-week period ending June 12, 2022.BioSpaceDr. Reddy’s Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.Dr. Reddy's entered a licensing agreement with Slayback Pharma to acquire exclusive rights to the first-to-file ANDA for the private label version of Lumify in the U.S. The ANDA is under FDA review, and the U.S. total addressable market is approximately $130 million for the 52 weeks ending June 12, 2022.PR NewswireSlayback Appoints Paul Campanelli to Board of DirectorsSlayback Pharma LLC, a Princeton, NJ-based specialty pharmaceutical company, announced the appointment of Paul Campanelli to its Board of Directors. Campanelli is a pharmaceutical industry veteran who previously served as President and CEO of Endo Pharmaceuticals and CEO of Par Pharmaceutical Companies, where he built a sterile injectable business that grew to over $1 billion in revenue before being acquired by Endo for over $8 billion in 2015. The company stated that Campanelli's extensive experience in growing specialty pharmaceutical businesses will support Slayback's growth trajectory.PR NewswireSlayback Appoints Dave Picard as Chief Commercial OfficerSlayback Pharma LLC announced the appointment of Dave Picard as Chief Commercial Officer, based at the company's Princeton office. Picard brings over 13 years of experience from Sandoz, where he led generic injectable sales including the launch of generic Enoxaparin, and most recently served as Senior Vice President of Global Generic Pharmaceuticals at AmerisourceBergen. He will lead Slayback's commercial function and strategy to support the company's growth in complex generic and specialty pharmaceutical products.PR NewswireSlayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla®Slayback Pharma LLC announced the launch of Merzee, a generic version of Allergan's Taytulla® oral contraceptive (norethindrone acetate and ethinyl estradiol capsules 1 mg/20 mcg with ferrous fumarate), and stated it has fulfilled customer orders for the product. The launch triggered a 180-day period of Competitive Generic Therapy (CGT) exclusivity for Slayback Pharma. CEO Ajay Singh said the company remains focused on bringing high-quality and affordable generics to the US market.